IPR2022-00964 - Eyenovia Inc v. Sydnexis IncReport Error
Details
PATENT NUMBER
APPL. NUMBER
15208537
STATUS
Not Instituted - Procedural § 325(d)
FILING DATE
2022-05-03
INSTITUTION DATE
2022-11-07
TERMINATION DATE
2022-11-07
AUTHOR JUDGE
Timeline
Petition
Notice of Filing Date
Preliminary Response
Institution Decision
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2023
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2024
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Docket
| 1 | 2022-05-03 | Petitioner | Petition | Petition for Inter Partes Review of U.S. Patent No. 9,770,447 |
| 2 | 2022-05-03 | Petitioner | Power of Attorney | Petitioner's Power of Attorney |
| 1001 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447 to Ostrow et al. | |
| 1002 | 2022-05-03 | Petitioner | Declaration of Dr. Stephen Byrn, Ph. D. | |
| 1003 | 2022-05-03 | Petitioner | Chia et al., Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2), OPHTHALMOLOGY 119(2): 347���354 (2012) | |
| 1004 | 2022-05-03 | Petitioner | Albert A. Kondritzer & Peter Zvirblis, Stability of Atropine in Aqueous Solution, J. AM. PHARM. ASS���N 46(9):531���535 (1957) | |
| 1005 | 2022-05-03 | Petitioner | John D. Mullins & Gerald Hecht, Pharmaceutical Necessities and Ophthalmic Preparations, in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, VOLUME II 1380���1416, 1563���1576 (Alfonso R. Gennaro ed., 19th ed. 1995) | |
| 1006 | 2022-05-03 | Petitioner | Siegel et al., Stability of Procaine in Deuterium Oxide, J. PHARM. SCIS. 53(8):978���979 (1964) | |
| 1009 | 2022-05-03 | Petitioner | McBrien et al., Point-Counterpoint. How does atropine exert its anti-myopia effects?, OPHTHALMIC & PHYSIOL OPT. 33:373���378 (2013) | |
| 1010 | 2022-05-03 | Petitioner | Chua et al., Atropine for the Treatment of Childhood Myopia, OPHTHALMOLOGY 113(12):2285���2291 (2006) | |
| 1011 | 2022-05-03 | Petitioner | Shih et al., An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression, ACTA OPHTHALMOLOGICA SCANDINAVICA 79:233���236 (2001) | |
| 1012 | 2022-05-03 | Petitioner | U.S. Patent Publication No. 2007/0254914 to Wu et al. | |
| 1013 | 2022-05-03 | Petitioner | Lee et al., Prevention of Myopia Progression with 0.05% Atropine Solution, J OCUL PHARMACOL THER. 22(1):41���46 (2006) | |
| 1014 | 2022-05-03 | Petitioner | Fang et al., Prevention of Myopia Onset with 0.025% Atropine in Premyopic Children, J OCUL PHARMACOL THER. 26(4):341���345 (2010) | |
| 1015 | 2022-05-03 | Petitioner | Shih et al., Effects of Different Concentrations of Atropine on Controlling Myopia in Myopic Children, J OCUL PHARMACOL THER. 15(1):85���90 (1999) | |
| 1016 | 2022-05-03 | Petitioner | Wu et al., The Long-Term Results of Using Low-Concentration Atropine Eye Drops for Controlling Myopia Progression in Schoolchildren, J OCUL PHARMACOL THER. 27(5):461���466 (2011) | |
| 1017 | 2022-05-03 | Petitioner | Chia et al., Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%, AM. J. OPHTHALMOLOGY 157(2):451���457.e1 (2014) | |
| 1018 | 2022-05-03 | Petitioner | International Publication No. WO 2012/161655 to Donald Tan and Wei Han Chua | |
| 1019 | 2022-05-03 | Petitioner | Zvirblis et al., The Kinetics of the Hydrolysis of Atropine, J. AM. PHARM. ASS���N 45(7): 450���454 (1956) | |
| 1020 | 2022-05-03 | Petitioner | Schier et al., Preparing for Chemical Terrorism: Stability of Injectable Atropine Sulfate, ACAD. EMERG. MED. 11(4):329���334 (2004) | |
| 1021 | 2022-05-03 | Petitioner | Kushner et al., Pharmacological uses and perspectives of heavy water and deuterated compounds, CAN. J. PHYSIOL. PHARMACOL. 77:79���88 (1999) - Part 1 | |
| 1022 | 2022-05-03 | Petitioner | Blake et al., Studies with Deuterated Drugs, J. PHARM. SCIS. 64(3):367���391 (1975) | |
| 1023 | 2022-05-03 | Petitioner | Thomas G. Gant, Using Deuterium in Drug Discovery: Leaving the Label in the Drug, J. MED. CHEM. 57(9):3595���3611 (2014) | |
| 1024 | 2022-05-03 | Petitioner | Allan B. Foster, Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design, ADVANCES IN DRUG RESEARCH 14:1���40 (1985) | |
| 1025 | 2022-05-03 | Petitioner | Katherine B. J. Schowen, Solvent Hydrogen Isotope Effects, TRANSITION STATES OF BIOCHEM. PROCESSES 225���283 (Richard D. Gandour & Richard L. Schowen eds., 1978) | |
| 1026 | 2022-05-03 | Petitioner | Paul K. Glasoe & F. A. Long, Use Of Glass Electrodes To Measure Acidities In Deuterium Oxide, J. PHYS. CHEM. 64(1):188���190 (1960) | |
| 1027 | 2022-05-03 | Petitioner | Sen et al., Role of heavy water in biological sciences with an emphasis on thermostabilization of vaccines, EXPERT REV. VACCINES 8(11): 1587���1602 (2009) - Part 1 | |
| 1028 | 2022-05-03 | Petitioner | U.S. Patent Publication No. 2011/0076331 to Bayerl | |
| 1029 | 2022-05-03 | Petitioner | Kho Kiat Nee, The Use Of Deuterium Oxide To Stabilize Pharmaceuticals Against Chemical Degradation, Slide Serve - Theophilus Stavros (2014) | |
| 1030 | 2022-05-03 | Petitioner | Peter Krumbiegel, Large deuterium isotope effects and their use: a historical review, ISOTOPES IN ENVTL. & HEALTH STUDIES 47(1):1���17 (2011) | |
| 1031 | 2022-05-03 | Petitioner | Amanda Yarnell, Heavy-Hydrogen Drugs Turn Heads, Again, CHEMICAL & ENG���G NEWS 87(25):36���39 (2009) | |
| 1032 | 2022-05-03 | Petitioner | Graham S. Timmins, Deuterated drugs; where are we now?, EXPERT OPIN. THER. PAT. 24(10):1067���1075 (2014) | |
| 1033 | 2022-05-03 | Petitioner | Anschel et al., Parenteral Formulation VI: Hydrolytic Degradation of Esters in Parenteral Solutions, BULLETIN OF THE PARENTERAL DRUG ASS���N 26(6):271���289 (1972) | |
| 1034 | 2022-05-03 | Petitioner | Filed Application of U.S. Patent No. 9,421,199, May 29, 2015 | |
| 1035 | 2022-05-03 | Petitioner | U.S. Patent No. 9,421,199, Non-Final Rejection, March 7, 2016 | |
| 1036 | 2022-05-03 | Petitioner | U.S. Patent No. 5,716,952 to WoldeMussie et al. | |
| 1037 | 2022-05-03 | Petitioner | U.S. Patent Publication No. 2012/0015035 to Wildsoet et al. | |
| 1038 | 2022-05-03 | Petitioner | U.S. Patent Publication No. 2012/0203161 to Herekar | |
| 1039 | 2022-05-03 | Petitioner | U.S. Patent No. 9,421,199, Response to Non-Final Rejection, April 5, 2016 | |
| 1040 | 2022-05-03 | Petitioner | U.S. Patent No. 9,421,199, Interview Summary, April 13, 2016 | |
| 1041 | 2022-05-03 | Petitioner | U.S. Patent No. 9,421,199, Notice of Allowance, June 13, 2016 | |
| 1042 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447, Advisory Action, April 13, 2017 | |
| 1043 | 2022-05-03 | Petitioner | Provisional Patent Application No. 60/016,502 | |
| 1044 | 2022-05-03 | Petitioner | Provisional Patent Application No. 62/096,433 | |
| 1045 | 2022-05-03 | Petitioner | Certified English Translation of CN 101049287A to Wu Peichang et al. | |
| 1046 | 2022-05-03 | Petitioner | Chowhan et al., Ophthalmic Preparations, in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 907929 (22nd ed. 2013) | |
| 1047 | 2022-05-03 | Petitioner | Lallemand et al., Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb, J. DRUG DELIVERY 2012:1���16 (2012) | |
| 1048 | 2022-05-03 | Petitioner | Rajpal et al., Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence, PATIENT PREFER ADHERENCE 8:925���31 (2014) | |
| 1049 | 2022-05-03 | Petitioner | Kirchhoff et al., Analysis of atropine, its degradation products and related substances of natural origin by means of reversed-phase high-performance liquid chromatography, J. CHROMATOGRAPHY A 1046:115���120 (2004) | |
| 1050 | 2022-05-03 | Petitioner | Garcia-Valldecabres et al., pH Stability of ophthalmic solutions, OPTOMETRY 75(3):161���168 (2004) | |
| 1051 | 2022-05-03 | Petitioner | PB Patel et al., Ophthalmic Drug Delivery System: Challenges and Approaches, SYSTEMATIC REVIEWS IN PHARMACY 1(2):113���120 (2010) | |
| 1052 | 2022-05-03 | Petitioner | European Patent Publication No. 0332826 to Zev Tashma | |
| 1053 | 2022-05-03 | Petitioner | PHYSIOCHEMICAL PRINCIPLES OF PHARMACY 56���92 (4th ed. 2006) | |
| 1054 | 2022-05-03 | Petitioner | Stephen S. Minor & Richard L. Schowen, One-Proton Solvation Bridge in Intramolecular Carboxylate Catalysis of Ester Hydrolysis, J. AM. CHEM. SOC. 95(7):2279���2281 (1973) | |
| 1055 | 2022-05-03 | Petitioner | DRUG REPOSITIONING BRINING NEW LIFE TO SHELVED ASSETS AND EXISTING DRUGS 53���64, 291���343 (Michael J. Barratt & Donald E. Frail eds., 2012) | |
| 1056 | 2022-05-03 | Petitioner | Cath O���Driscoll, Heavyweight drugs, CHEM. & INDUS. 24���26 (2009) | |
| 1057 | 2022-05-03 | Petitioner | UK Patent Application GB 2293100 to Ian George Stephen Furminger & Philip James Sizer | |
| 1058 | 2022-05-03 | Petitioner | U.S. Patent No. 7,691,099 to Berry | |
| 1059 | 2022-05-03 | Petitioner | U.S. Patent Publication No. 2012/0135084 to Bayerl | |
| 1060 | 2022-05-03 | Petitioner | June G. Winter and J. M. W. Scott, Studies in Solvolysis. Part IV. Substituent and Solvent Isotope Effects in the Solvolysis of a Series of Benzyl Trifluroacetates, CAN. J. CHEM. 50:1886���90 (1972) | |
| 1061 | 2022-05-03 | Petitioner | William P. Jencks & Joan Carriuolo, General Base Catalysis of Ester Hydrolysis, J. AM. CHEM. SOC. 83(7):1743���50 (1961) | |
| 1062 | 2022-05-03 | Petitioner | Bender et al., Deuterium Oxide Solvent Isotope Effects in the Nucleophilic Reactions of Phenyl Esters, J. AM. CHEM. SOC. 84(4):595���599 (1962) | |
| 1063 | 2022-05-03 | Petitioner | June G. Winter & J. M. W. Scott, Studies in solvolysis. Part I. The neutral hydrolysis of some alkyl trifluoroacetates in water and deuterium oxide, CANADIAN J. CHEM. 46:2887���2894 (1968) | |
| 1064 | 2022-05-03 | Petitioner | Bradley A. Hanson et al., A Mechanistic and Kinetic Study of the E-Ring Hydrolysis and Lactonization of a Novel Phosphoryloxymethyl Prodrug of Camptothecin, PHARM. RESEARCH 20(7):1031���1038 (2003) | |
| 1065 | 2022-05-03 | Petitioner | English Translation of Jinshen Li, Preparation and Quality Control of 0.04% Atropine Sulfate Eye Drops, CHINA PHARMACY 17(2):111���113 (2006) | |
| 1066 | 2022-05-03 | Petitioner | Atropine Sulfate Ophthalmic Solution, Highlights of Prescribing Information, Revised July 2014 | |
| 1067 | 2022-05-03 | Petitioner | Certified English Translation of Yuanda Wen, Preparation and Clinical Curative Effects of 0.05% Atropine Sulfate Eye Drops, CHINA PHARMACIST 11(2):194���196 (2008) | |
| 1068 | 2022-05-03 | Petitioner | Ronald F. Donnelly & C��line Corman, Physical Compatibility and Chemical Stability of a Concentrated Solution of Atropine Sulfate (2 mg/mL) for Use as an Antidote in Nerve Agent Casualties, INT���L J. PHARM. COMPOUNDING 12(6):550���552 (2008) | |
| 1069 | 2022-05-03 | Petitioner | M. R. W. Brown & D. A. Norton, The Preservation of Ophthalmic Preparations, J. SOC. COSMETIC CHEMISTS 16:369���393 (1965) | |
| 1070 | 2022-05-03 | Petitioner | A. J. Kresge, Solvent Isotope Effect in H2O-D2O Mixtures, PURE APPL. CHEM. 8(3-4):243���258 (1964) | |
| 1071 | 2022-05-03 | Petitioner | Driver et al., The Stability of Atropine Sulfate Solutions Stored in Plastic Syringes in the Operating Room, ANESTH. ANALG. 89:1056���1058 (1999) | |
| 1072 | 2022-05-03 | Petitioner | Food Drug Administration Center for Drugs Evaluation Research GUIDANCE FOR INDUSTRY: DRUG STABILITY GUIDELINES (DECEMBER 9, 2008) | |
| 1073 | 2022-05-03 | Petitioner | DICTIONARY OF CHEMISTRY (2nd ed. 2003) | |
| 1074 | 2022-05-03 | Petitioner | Sodium phosphate monobasic Safety Data Sheet, Version 1.1, G-BIOSCIS. (Jan. 9, 2012) | |
| 1075 | 2022-05-03 | Petitioner | Sodium Phosphate Dibasic, Anhydrous Material Safety Data Sheet, SCHOLAR CHEM. (Jan. 23, 2009) | |
| 1076 | 2022-05-03 | Petitioner | Pfannkoch, The Preparation of Buffers and Other Solutions: A Chemist���s Perspective, MOLECULAR BIOLOGY PROBLEM SOLVER: A LABORATORY GUIDE Ch. 3:31���47 (Alan S. Gerstein ed., 2001) | |
| 1077 | 2022-05-03 | Petitioner | HANDBOOK OF PHARMACEUTICAL EXCIPIENTS 5���7, 193���196, 281���284, 351���352, 741���742, 984���989 (Raymond C. Rowe et al. eds., 7th ed. 2012) - Part 1 | |
| 1078 | 2022-05-03 | Petitioner | International Patent Publication No. WO 2013/167865 to Purandare | |
| 1079 | 2022-05-03 | Petitioner | U.S. Patent Publication No. 2008/0300316 to Gant et al. | |
| 1080 | 2022-05-03 | Petitioner | Waterman et al., Hydrolysis in Pharmaceutical Formulations, PHARM. DEV. & TECH. 7(2):113���146 (2002) | |
| 1081 | 2022-05-03 | Petitioner | Lin et al., Formulation and stability of an extemporaneous 0.02% chlorhexidine digluconate ophthalmic solution, J. FORMOSAN MED. ASS���N 114:1162���1169 (2015) | |
| 1082 | 2022-05-03 | Petitioner | Susina et al., Effect of Deuterium Oxide on Local Anesthetic Activity of Procaine, J. PHARM. SCIS. 51(12):1166���1169 (1962) | |
| 1083 | 2022-05-03 | Petitioner | Dimitrios Stefanidis & William P. Jencks, General Base Catalysis of Ester Hydrolysis, J. AM. CHEM. SOC. 115:6045���6050 (1993) | |
| 1084 | 2022-05-03 | Petitioner | Berton et al., Stability of Ophthalmic Atropine Solutions for Child Myopia Control, PHARMACEUTICS 12(8):781 (2020) | |
| 1085 | 2022-05-03 | Petitioner | John D. Mullins & Gerald Hecht, Tonicity, Osmoticity, Osmolality and Osmolarity and Stability of Pharmaceutical Products, in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, VOLUME I 613���627, 639���647 (Alfonso R. Gennaro ed., 19th ed. 1995) | |
| 1086 | 2022-05-03 | Petitioner | Atropine Sulfate Ophthalmic Solution, Highlights of Prescribing Information, Revised July 2014, Wayback Machine and Affidavit | |
| 1087 | 2022-05-03 | Petitioner | Badar�� et al., Retinal Biocompatibility of Brilliant Blue G with Deuterated Water for Chromovitrectomy, J. OPHTHALMIC & VISION RESEARCH 9(2):204���209 (2014) | |
| 1088 | 2022-05-03 | Petitioner | International Publication No. WO 94/21298 to Karl Simpson & Radu Crainic | |
| 1089 | 2022-05-03 | Petitioner | U.S. Application No. 16/805,612, Information Disclosure Statement, March 2, 2020 | |
| 1090 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447, Preliminary Amendment and Response to Notice to File Missing Parts, August 3, 2013 | |
| 1091 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447, Non-Final Office Action, September 30, 2016 | |
| 1092 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447, Information Disclosure Statement and International Search Report, November 17, 2016 | |
| 1093 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447, Final Rejection, January 25, 2017 | |
| 1094 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447, Response to Final Office Action, March 21, 2017 | |
| 1095 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447, AFCP2.0 Response to Final Office Action Dated and Advisory Action, April 21, 2017 | |
| 1096 | 2022-05-03 | Petitioner | Peter Zvirblis & Robert I. Ellin, Kinetics and Stability of a Multicomponent Organophosphate Antidote Formulation in Glass and Plastic, J. PHARM. SCIS. 71(3):321���325 (1982) | |
| 1097 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447, Notice of Allowance, May 30, 2017 | |
| 1098 | 2022-05-03 | Petitioner | U.S. Patent No. 9,770,447, Certificate of Correction | |
| 3 | 2022-05-11 | Board | Notice of Filing Date | Notice: Notice filing date accorded |
| 4 | 2022-05-17 | Potential Patent Owner | Mandatory Notice | Patent Owner's Mandatory Notices |
| 5 | 2022-05-17 | Potential Patent Owner | Power of Attorney | Patent Owner's Power of Attorney |
| 6 | 2022-08-11 | Potential Patent Owner | Preliminary Response | Patent Owner's Preliminary Response |
| 2001 | 2022-08-11 | Potential Patent Owner | EX2001 - US 9,421,199 File History | |
| 2002 | 2022-08-11 | Potential Patent Owner | EX2002 - Lund et al | |
| 2003 | 2022-08-11 | Potential Patent Owner | EX2003 - US 9,770,447 File History | |
| 2005 | 2022-08-11 | Potential Patent Owner | EX2005 - US 10,251,875 File History | |
| 2006 | 2022-08-11 | Potential Patent Owner | EX2006 - IPR2022-00384 EX1002 - Byrn Declaration | |
| 7 | 2022-11-07 | Board | Institution Decision | Institution Decision: Denying Institution of Inter Partes Review 35 U.S.C. sec. 314 |
| 8 | 2022-11-22 | Petitioner | Other | Petitioner's Request for Refund of Post-Institution Fee |
Grounds Asserted